Sequencer Products
Technologies
Popular Applications
Research Applications
Documents 
Publications
Customer Stories
Online Datasheets
User Center
Customer Center
Self-service
SHENZHEN, CHINA, 28th, September 2021-The COVID-19 pandemic remains severe and complex in many parts of Southeast Asia and beyond, posing a formidable challenge to the public health system. Diagnostic testing remains to be crucial in fighting against the COVID-19 pandemic. As an important measure for the COVID-19 control and prevention, how to improve the capacity of nucleic acid detection has attracted great attention from all countries.
MGI, a world-leading life science technology innovator, has recently provided its innovative automation systems to support the COVID-19 control and prevention in Singapore, Thailand, and Malaysia.
To enhance large-scale COVID-19 testing capacity, MGI provided M Diagnostics in Singapore, PCT Laboratory in Thailand, and Neoscience in Malaysia with its proprietary automation systems including MGISTP-3000 Automated Sample Transfer Processing System, MGISP-960 High-throughput Automated Sample Preparation System, and MGISP-NE384 High-throughput Automated Nucleic Acid Extractor. MGI's highly automated systems can avoid human contact with samples to reduce human errors and infection risk, thus ensuring a safer working environment for lab technicians.
The extraction of virus nucleic acid is a key step in the COVID sample testing process. MGISP-NE384 is a high-throughput automated nucleic acid extractor, using the magnetic rod technology. Together with the nucleic acid extraction kit, MGISP-NE384 can extract and purify nucleic acid from 96, 192, 288 or 384 samples at one given time. The built-in HEPA filtration system and UV lamp ensure a safe working environment for nucleic acid extraction and lab technicians. As the first fully automated nucleic acid extractor in the market being utilized on the front line of COVID-19 fight, one MGISP-NE384 can process 10,000 samples per day.
MGI's High-throughput Automated Nucleic Acid Extractor, MGISP-NE384
MGI automated laboratory systems simplify the labor-intensive and time-consuming procedures in a diagnostic testing laboratory such as sample preparation, DNA/RNA extraction, and liquid transfer, and enable a highly efficient streamlined workflow. MGISTP-3000 automated sample transfer processing system is equipped with an intuitive user interface and a 23-inch touch screen. It is easy to operate and can transfer up to 96 samples from airtight sample tubes to 96-well microplates. MGISTP-3000 can process 3500 samples a day or 10000 samples in 8 hours if 10 samples are integrated in one tube for batch testing. It can seamlessly connect to all kinds of subsequent liquid handling workstations and nucleic acid extractors.
MGISTP-3000 Automated Sample Transfer Processing System
MGISP-960 is an automated workstation with a 96-channel pipettor head, used to extract nucleic acid, or the genetic material from the sample, and it can accommodate different sample batches to process 192 samples in 80 minutes or 32-96 samples in 55 minutes. MGISP-960 supports a wide range of library kits including WES, WGS and RNA. It is a highly-efficient and widely-used automated sample preparation system contributing to the current COVID-19 testing.
MGISP-960 High-throughput Automated Sample Preparation System
Founded in 2016, MGI operates in more than 70 countries and regions, and has established scientific research and production bases, global training, and service network around the world. MGI has also played an integral role in the global combat against COVID-19 by speeding up the efficiency of large-scale testing while ensuring a safer working environment for lab technicians. MGI's automation systems have been supporting more than 50 countries to date, including Sweden, United Arab Emirates, Canada, Serbia, and Australia, contributing to safeguarding the global community.
About MGI
Headquartered in Shenzhen, MGI is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on Research & Development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing*, medical imaging, and laboratory automation. MGI's mission is to develop and promote advanced life science tools for future healthcare. For more information please visit MGI or connect with us on Twitter, Linkedin or Youtube.
*Unless otherwise informed, all sequencers and sequencing reagents are not available in Germany, USA, Spain, UK, Hong Kong, Sweden, and Belgium.
